Gefitinib has been widely used in the first-line treatment of advanced EGFRmutated non-small-cell lung cancer (NSCLC). However, many NSCLC patients will acquire resistance to gefitinib after 9-14 months of treatment. This study revealed that Kr€ uppel-like factor 4 (KLF4) contributes to the formation of gefitinib resistance in c-Met-overexpressing NSCLC cells. We observed that KLF4 was overexpressed in shows strong therapeutic effects against NSCLC with an activating EGFR mutation. 4,5 However, many NSCLC patients will acquire resistance to gefitinib after a median of 9-14 months of treatment. 6 The T790M of EGFR is the most common EGFR-TKI resistance mechanism, which confers resistance by increasing the ATP affinity. 7 Furthermore, c-Met amplification is a frequently reported mechanism of acquired resistance to EGFR-TKI and has been reported in approximately 20% of NSCLC cases following EGFR-TKI treatment. 8,9 c-Met
amplification causes EGFR-TKI resistance because c-Met amplification can increase the expression of c-Met protein which can activate the Erb-B2 receptor tyrosine kinase 3 (ERBB3)/PI3K/Akt signaling pathway, and this pathway is also the downstream signaling pathway of EGFR. 10 Kr€ uppel-like factor 4 (KLF4), as a transcription factor, is expressed in the epithelium of a variety of tissues 11 and has multiple roles in physiological and disease processes, such as cellular processes, vascular functions, and tumorigenesis. 11, 12 However, current studies have reported the dual nature of KLF4 as either an oncogene or a tumor suppressor gene with an unclear mechanism in tumorigenesis. 12, 13 KLF4 functions as a tumor suppressor gene to suppress the proliferation, invasion, and metastasis of tumor cells in kidney cancer, 14 gastric cancer, 15 and prostate cancer, 16 but it was identified as an oncogene in breast cancer. 17 Paradoxically, KLF4 functions as both an oncogene and tumor suppressor gene in colon cancer 18, 19 and skin cancer. 20, 21 Several studies have shown that tumor tissues had lower KLF4 levels compared with normal adjacent tissues. [22] [23] [24] KLF4 might function as a tumor suppressor gene to suppress lung cancer growth by inhibiting human telomerase reverse transcriptase (hTERT) and MAPK signaling. 22 KLF4 deletion can promote lung cancer formation and progression by activating the mutated oncogene KRAS. 23 Another study revealed that activation of oncogenic c-Met could increase KLF4 expression in glioblastoma cells and glioblastoma stem cells. 25, 26 The present study aimed to examine what role KLF4 plays in cMet amplification-mediated gefitinib-resistant NSCLC patients and elucidate the underlying molecular mechanisms to provide a theoretical basis for molecule inhibitors targeting transcription factors and protein kinases as antitumor therapy.
| MATERIALS AND METHODS

| Tissue collection and ethics statement
Eighteen primary NSCLC patients undergoing tumor resection were recruited at the Third Xiangya Hospital of Central South University 
| c-Met genomic amplification assay
Genomic DNA was extracted from NSCLC cells and resected tumor tissues using a MiniBEST Universal Genomic DNA Extraction Kit 27 Data were analyzed by relative quantitation using the DDCt method. 27 A value >2 was considered as the c-Met genomic amplification.
| Chemicals and cell lines
Gefitinib was obtained from Selleck Chemicals (Houston, TX, USA).
Epidermal growth factor was obtained from Peprotech (Rocky Hill, NJ, USA). Cell lines from ATCC (Gaithersburg, MD, USA) were cultured in DMEM (293T), Eagle's minimum essential medium (MRC5), or RPMI-1640 (A549, H460, H1299, H1975, H1993, HCC4006, and HCC827) containing 10% FBS. We generated the gefitinib-resistant HCC827 cells (HCC827GR) from the gefitinib-sensitive HCC827 cells by exposing it to increasing concentrations of gefitinib for 6 months. 28 
| Lentiviral infection
Lentivirus packaging was carried out as previously described. 
| Cell proliferation assay
Cell proliferation was assessed using MTS and clonogenic assays. For the MTS assay, stably transfected NSCLC cell lines were seeded (2- the nude mice in each group were randomized into two different subgroups (6 mice/subgroup) and treated with gefitinib (50 mg/kg/day) or vehicle (0.5% Tween-80) for 3 weeks by oral gavage, as previously described. 30 The tumor length and width of each mouse were measured weekly by a digital caliper. The tumor volumes (V) were calculated using the following formula: V = length 9 width 2 / 2. The relative tumor volume (RTV) was calculated by the following formula: RTV = Vw / V0, in which Vw represents the volume each week, and V0 is the initial tumor volume at the beginning of gefitinib treatment.
All nude mice were killed 3 weeks after the initial gefitinib treatment, and the tumor tissues were collected for analysis.
| Statistical analysis
Results were analyzed using SPSS version 18 statistical software (IBM SPSS, Chicago, IL, USA). Normally distributed continuous variables were compared using ANOVA or least significant difference t-test, as appropriate. The statistical results are expressed as the mean AE SD of three independent experiments. A probability level of P < .05 was considered statistically significant.
3 | RESULTS
| Overexpression of KLF4 in NSCLC cells with c-Met overexpression
To study the function of KLF4 in gefitinib-resistant NSCLC cells, we Ex19 del, in-frame deletion in exon 19; KRasG12V, G12V point mutation in exon 2; KRasQ61H, Q61H point mutation in exon 3; L858R, L858R point mutation in exon 21; T790M, T790M point mutation in exon 20. knockdown of KLF4 had no effect on the apoptosis rate of these NSCLC cells after gefitinib treatment ( Figure S2 ). These results indicated that KLF4 increased the gefitinib resistance of c-Met-overexpressing NSCLC cells by inhibiting gefitinib-induced apoptosis.
| Kr€ uppel-like factor 4
Regulates the c-Met/Akt signaling pathway in HCC827GR and HCC827 cell lines. Previous results confirmed that KLF4 was a critical factor in the formation of gefitinib resistance in c-Met-overexpressing NSCLC cells, but the mechanism was unclear.
Consequently, we investigated the function of KLF4 in the EGFR NSCLC without EGFR-TKI treatment. 7 as our study showed (Figure 1C) , which can result in primary resistance of NSCLC to EGFR-TKI.
Previous studies revealed that KLF4, a Kr€ uppel-like transcription factor, has multiple roles in cellular processes, vascular functions, and inflammatory reactions. 11 Furthermore, as an ambiguous cancerassociated gene, KLF4 functions as a context-dependent oncogene or tumor suppressor gene in different cancer types. 12, 13 In the present study, we observed that knockdown of KLF4 increases tumorigenic properties in NSCLC cells without c-Met overexpression ( Figure S1 ). Recent studies have shown that KLF4 directly binds to the promoter region of hTERT and suppresses hTERT expression. 22, 23 We also observed that hTERT was upregulated by knockdown of KLF4 in NSCLC cells without c-Met overexpression ( Figure S1 ). Therefore, the mechanism of KLF4, when functioning as Figure 4B,D) . This anti-apoptotic activity of KLF4 could be explained by its ability to suppress p53 expression by directly acting on the promoter 41 and inhibiting p53 to transactivate expression of the pro-apoptotic gene BAX.
42
One of the most important mechanisms of gefitinib resistance in NSCLC patients is the c-Met amplification, which leads to activation of the EGFR downstream PI3K/Akt signaling pathway. 10 However, the molecular mechanisms responsible for c-Met amplification in NSCLC patients after receiving gefitinib treatment have not been fully elucidated. Research showed that knockdown of KLF4 inhibited the PI3K/ Akt signaling pathway by regulating the promoter region of p110d in this pathway. 43 In the present study, we observed that knockdown of 
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